Back

PANCS-Inhibitors: A rapid method to directly select for protein-protein interaction inhibitors

Styles, M. J.; Xie, V. C.; Legault, S.; Pixley, J. A.; Dickinson, B. C.

2026-08-06 synthetic biology
10.64898/2026.08.05.743105 bioRxiv
Show abstract

Aberrant protein-protein interactions (PPIs) drive myriad diseases. Inhibiting these PPIs often relies on discovering molecules that bind to one of the proteins and hoping that this binding inhibits the PPI. Molecular binder discovery often takes months, but a discovery process that ensures that the resulting molecule not only binds a target protein, but selectively inhibits a target PPI, could dramatically accelerate these endeavors. Here, we develop Phage-Assisted Non-Continuous Selection of PPI Inhibitors (PANCS-Inhibitors): a rapid screening platform that directly selects for molecules capable of disrupting a pre-formed PPI. We demonstrate this new platform using three clinically relevant oncogenic PPIs: KRas-Raf, Mdm2-p53, and Myc-Max. PANCS-Inhibitors can be used to both improve known PPI inhibitors and for de novo discovery of mini-protein PPI inhibitors that function in mammalian cells. This platform has the potential to rapidly generate inhibitors for many clinically relevant PPIs, which can be used as starting points for therapeutic development.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.